LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials LRRK2 PROTAC (ARV-102): From Target Degradation to Biomarker-Driven Trials Curator: Warren Peters, MD, MPH, FOMA Silo: Voice of Health – Research Edition Research Summary ARV-102 is a proteolysis-targeting chimera (PROTAC) that binds LRRK2 and recruits an E3 ligase, tagging the protein for degradation. Unlike traditional kinase inhibitors, it reduces the total …

A New Approach in Parkinson’s: Removing a Problem Protein (LRRK2) A New Approach in Parkinson’s: Removing a Problem Protein Silo: Voice of Health – Patient Edition What’s Being Studied Scientists are testing a new therapy called ARV-102. It helps cells identify and remove a protein called LRRK2 that may contribute to Parkinson’s. The first trial involved healthy adults to make …

Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that aim to help us live not only longer, but better. …

Healthspan Is Becoming Real: What the GLP-1 Shift Means Healthspan Is Becoming Real: What the GLP-1 Shift Means At a leading aging research meeting, major drug makers described GLP-1 medicines as “longevity therapeutics.” That language shift matters: it opens the door to earlier prevention trials, better biomarkers, and treatments that aim to help us live not only longer, but better. …

Working Together for Better Alzheimer’s Care: The ADRC Team Approach Working Together for Better Alzheimer’s Care Source: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Silo: Voice of Health (Patient Edition) Why “Team Science” Matters Alzheimer’s affects memory, independence, and families. No single expert can solve it alone. In South Carolina, researchers and …

Citation: Athauda D et al., 2025, New England Journal of Medicine, DOI 10.1056/NEJMoa2306791Research Summary:A randomized double-blind Phase 2 trial evaluated lixisenatide, a GLP-1 receptor agonist, in 156 individuals Participants received lixisenatide or placebo over 12 months. The lixisenatide group maintained stable with a decline in the placebo group. Gastrointestinal effects were the most common adverse events. Motor after treatment ended.Clinical …

Team Science for Dementia: The ADRC Circular Loop (Discovery → Development → Delivery → Dissemination) Harnessing Team Science in Dementia Research: The ADRC Circular Loop Citation: Akter S, Bawa EM, Riccardi N, et al. Journal of Alzheimer’s Disease Reports. 2025;9. doi:10.1177/25424823251385902 Curator: Warren Peters, MD MPH FOMA • Silo: Voice of Health (Research Edition) SEO title (≤60): Team Science for …

Cognitive health during aging is not just about genes or willpower. It’s about where we’re born, live, learn, work, and age—the social determinants of health (SDOH)—and the policies that shape those conditions. Because social environments and access to resources differ widely, not everyone experiences healthy cognitive aging. This long-form guide synthesizes cutting-edge evidence on SDOH and dementia, and then translates …